Germany grants reimbursement for Delcath's chemo delivery tech

Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status, which allows treatment centers to negotiate coverage with insurers, though it falls short of a mandated reimbursement. Chemosat is a liver cancer drug delivery system for chemotherapy that got its CE mark last year and is awaiting FDA approval. The reimbursement pathway gives Delcath a significant foothold in the German market, which the company says is its most robust. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…